Vasundhara Rasayans Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
241.90 +0.40 (0.17%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
236.00
Today’s High
242.20
52 Week Low
179.00
52 Week High
398.00
Key Metrics
- Market Cap (In Cr) 76.97
- Beta 1.49
- Div. Yield (%) 0.83
- P/B 2.4
- TTM P/E 15.61
- Peg Ratio 0.5
- Sector P/E 0
- Open Price 236
- Prev Close 241.5
Vasundhara Rasayans Analysis
Price Analysis
-
1 Week0.19%
-
3 Months-20.51%
-
6 Month-10.54%
-
YTD-16.87%
-
1 Year13.92%
Risk Meter
- 44% Low risk
- 44% Moderate risk
- 44% Balanced Risk
- 44% High risk
- 44% Extreme risk
Vasundhara Rasayans Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 37.02
- Selling/ General/ Admin Expenses Total
- 3.28
- Depreciation/ Amortization
- 0.26
- Other Operating Expenses Total
- 11.09
- Total Operating Expense
- 30.89
- Operating Income
- 6.13
- Net Income Before Taxes
- 7.9
- Net Income
- 5.86
- Diluted Normalized EPS
- 18.44
- Period
- 2024
- Total Assets
- 37.3
- Total Liabilities
- 5.36
- Total Equity
- 31.94
- Tangible Book Valueper Share Common Eq
- 100.49
- Period
- 2024
- Cashfrom Operating Activities
- 6.03
- Cashfrom Investing Activities
- -1.32
- Cashfrom Financing Activities
- -2.88
- Net Changein Cash
- 1.83
- Period
- 2023
- Total Revenue
- 37.94
- Selling/ General/ Admin Expenses Total
- 2.6
- Depreciation/ Amortization
- 0.13
- Other Operating Expenses Total
- 11.46
- Total Operating Expense
- 32.56
- Operating Income
- 5.38
- Net Income Before Taxes
- 7.48
- Net Income
- 5.59
- Diluted Normalized EPS
- 17.59
- Period
- 2023
- Total Assets
- 34.52
- Total Liabilities
- 7.7
- Total Equity
- 26.82
- Tangible Book Valueper Share Common Eq
- 84.38
- Period
- 2023
- Cashfrom Operating Activities
- -6.5
- Cashfrom Investing Activities
- 1.27
- Cashfrom Financing Activities
- 2.19
- Net Changein Cash
- -3.04
- Period
- 2022
- Total Revenue
- 26.75
- Selling/ General/ Admin Expenses Total
- 2.27
- Depreciation/ Amortization
- 0.11
- Other Operating Expenses Total
- 8.39
- Total Operating Expense
- 24.7
- Operating Income
- 2.05
- Net Income Before Taxes
- 3.05
- Net Income
- 2.17
- Diluted Normalized EPS
- 6.84
- Period
- 2022
- Total Assets
- 25.5
- Total Liabilities
- 3.97
- Total Equity
- 21.54
- Tangible Book Valueper Share Common Eq
- 67.76
- Period
- 2022
- Cashfrom Operating Activities
- 7.9
- Cashfrom Investing Activities
- 1.39
- Cashfrom Financing Activities
- 0.79
- Net Changein Cash
- 10.08
- Period
- 2021
- Total Revenue
- 22.68
- Selling/ General/ Admin Expenses Total
- 3.88
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 5.04
- Total Operating Expense
- 19.7
- Operating Income
- 2.98
- Net Income Before Taxes
- 3.96
- Net Income
- 2.94
- Diluted Normalized EPS
- 9.24
- Period
- 2021
- Total Assets
- 25.13
- Total Liabilities
- 5.26
- Total Equity
- 19.87
- Tangible Book Valueper Share Common Eq
- 62.52
- Period
- 2021
- Cashfrom Operating Activities
- 0.22
- Cashfrom Investing Activities
- 0.16
- Cashfrom Financing Activities
- -0.49
- Net Changein Cash
- -0.12
- Period
- 2020
- Total Revenue
- 21.28
- Selling/ General/ Admin Expenses Total
- 3.49
- Depreciation/ Amortization
- 0.03
- Other Operating Expenses Total
- 5.71
- Total Operating Expense
- 18.5
- Operating Income
- 2.79
- Net Income Before Taxes
- 3.91
- Net Income
- 2.99
- Diluted Normalized EPS
- 9.4
- Period
- 2020
- Total Assets
- 24.69
- Total Liabilities
- 7.28
- Total Equity
- 17.41
- Tangible Book Valueper Share Common Eq
- 54.78
- Period
- 2020
- Cashfrom Operating Activities
- 0.36
- Cashfrom Investing Activities
- 1.02
- Cashfrom Financing Activities
- -0.87
- Net Changein Cash
- 0.5
- Period
- 2019
- Total Revenue
- 19.77
- Selling/ General/ Admin Expenses Total
- 3.43
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 5.88
- Total Operating Expense
- 18.7
- Operating Income
- 1.07
- Net Income Before Taxes
- 2.07
- Net Income
- 1.45
- Diluted Normalized EPS
- 4.57
- Period
- 2019
- Total Assets
- 20.83
- Total Liabilities
- 6.02
- Total Equity
- 14.81
- Tangible Book Valueper Share Common Eq
- 46.59
- Period
- 2019
- Cashfrom Operating Activities
- 0.43
- Cashfrom Investing Activities
- 0.53
- Cashfrom Financing Activities
- -1.36
- Net Changein Cash
- -0.41
- Period
- 2018
- Total Revenue
- 16.6
- Selling/ General/ Admin Expenses Total
- 2.73
- Depreciation/ Amortization
- 0.32
- Other Operating Expenses Total
- 4.34
- Total Operating Expense
- 15.44
- Operating Income
- 1.16
- Net Income Before Taxes
- 9.05
- Net Income
- 6.52
- Diluted Normalized EPS
- 21.21
- Period
- 2018
- Total Assets
- 20.38
- Total Liabilities
- 6.64
- Total Equity
- 13.74
- Tangible Book Valueper Share Common Eq
- 43.22
- Period
- 2018
- Cashfrom Operating Activities
- -10.7
- Cashfrom Investing Activities
- 13.3
- Cashfrom Financing Activities
- -2.26
- Net Changein Cash
- 0.33
- Period
- 2024-12-31
- Total Revenue
- 8.82
- Selling/ General/ Admin Expenses Total
- 0.64
- Depreciation/ Amortization
- 0.09
- Other Operating Expenses Total
- 2.94
- Total Operating Expense
- 7.34
- Operating Income
- 1.48
- Net Income Before Taxes
- 1.96
- Net Income
- 1.45
- Diluted Normalized EPS
- 4.57
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 9.78
- Selling/ General/ Admin Expenses Total
- 0.69
- Depreciation/ Amortization
- 0.09
- Other Operating Expenses Total
- 3.72
- Total Operating Expense
- 8.26
- Operating Income
- 1.53
- Net Income Before Taxes
- 1.98
- Net Income
- 1.47
- Diluted Normalized EPS
- 4.61
- Period
- 2024-09-30
- Total Assets
- 44.02
- Total Liabilities
- 7
- Total Equity
- 37.02
- Tangible Book Valueper Share Common Eq
- 116.48
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -8.63
- Cashfrom Investing Activities
- 0.94
- Cashfrom Financing Activities
- -0.13
- Net Changein Cash
- -7.82
- Period
- 2024-06-30
- Total Revenue
- 7.63
- Selling/ General/ Admin Expenses Total
- 0.85
- Depreciation/ Amortization
- 0.06
- Other Operating Expenses Total
- 2.66
- Total Operating Expense
- 6.83
- Operating Income
- 0.8
- Net Income Before Taxes
- 1.16
- Net Income
- 0.86
- Diluted Normalized EPS
- 2.71
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 11.14
- Selling/ General/ Admin Expenses Total
- 1.12
- Depreciation/ Amortization
- 0.08
- Other Operating Expenses Total
- 3.24
- Total Operating Expense
- 8.95
- Operating Income
- 2.19
- Net Income Before Taxes
- 2.86
- Net Income
- 2.13
- Diluted Normalized EPS
- 6.72
- Period
- 2024-03-31
- Total Assets
- 37.3
- Total Liabilities
- 5.36
- Total Equity
- 31.94
- Tangible Book Valueper Share Common Eq
- 100.49
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 6.03
- Cashfrom Investing Activities
- -1.32
- Cashfrom Financing Activities
- -2.88
- Net Changein Cash
- 1.83
- Period
- 2023-12-31
- Total Revenue
- 8.23
- Selling/ General/ Admin Expenses Total
- 0.93
- Depreciation/ Amortization
- 0.08
- Other Operating Expenses Total
- 2.49
- Total Operating Expense
- 6.85
- Operating Income
- 1.37
- Net Income Before Taxes
- 1.87
- Net Income
- 1.38
- Diluted Normalized EPS
- 4.35
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 9.32
- Selling/ General/ Admin Expenses Total
- 0.63
- Depreciation/ Amortization
- 0.06
- Other Operating Expenses Total
- 2.84
- Total Operating Expense
- 7.69
- Operating Income
- 1.63
- Net Income Before Taxes
- 1.88
- Net Income
- 1.39
- Diluted Normalized EPS
- 4.37
- Period
- 2023-09-30
- Total Assets
- 38.07
- Total Liabilities
- 6.84
- Total Equity
- 31.23
- Tangible Book Valueper Share Common Eq
- 98.27
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -4.32
- Cashfrom Investing Activities
- -0.24
- Cashfrom Financing Activities
- -0.09
- Net Changein Cash
- -4.65
- Period
- 2023-06-30
- Total Revenue
- 8.33
- Selling/ General/ Admin Expenses Total
- 0.61
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 2.52
- Total Operating Expense
- 7.4
- Operating Income
- 0.93
- Net Income Before Taxes
- 1.29
- Net Income
- 0.96
- Diluted Normalized EPS
- 3.01
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 9.91
- Selling/ General/ Admin Expenses Total
- 0.91
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 3.26
- Total Operating Expense
- 9.38
- Operating Income
- 0.53
- Net Income Before Taxes
- 0.5
- Net Income
- 0.43
- Diluted Normalized EPS
- 1.35
- Period
- 2023-03-31
- Total Assets
- 34.52
- Total Liabilities
- 7.7
- Total Equity
- 26.82
- Tangible Book Valueper Share Common Eq
- 84.38
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -6.5
- Cashfrom Investing Activities
- 1.27
- Cashfrom Financing Activities
- 2.19
- Net Changein Cash
- -3.04
- Period
- 2022-12-31
- Total Revenue
- 8.11
- Selling/ General/ Admin Expenses Total
- 0.63
- Depreciation/ Amortization
- 0.03
- Other Operating Expenses Total
- 2.72
- Total Operating Expense
- 6.16
- Operating Income
- 1.95
- Net Income Before Taxes
- 2.33
- Net Income
- 1.72
- Diluted Normalized EPS
- 5.43
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Vasundhara Rasayans Technical
Moving Average
SMA
- 5 Day240.14
- 10 Day241.96
- 20 Day244.56
- 50 Day252.01
- 100 Day271.23
- 300 Day284.56
Vasundhara Rasayans Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Achyut Healthcare
- 3.66
- 0
- 0
- 6.25
- 2.82
- 85.98
- Biofil Chemicals And Pharma
- 48.53
- -2.32
- -4.56
- 92
- 40.5
- 78.97
- Vasundhara Rasayans
- 241.9
- 0.4
- 0.17
- 398
- 179
- 76.97
- Sunil Healthcare
- 76.8
- 5.89
- 8.31
- 104
- 60.55
- 79.41
- Godavari Drugs
- 95
- 1.92
- 2.06
- 155
- 79
- 71.54
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Achyut Healthcare
- 137.51
- 2.56
- -
- -
- Biofil Chemicals And Pharma
- 109.48
- 4.27
- 5.45
- 2.8
- Vasundhara Rasayans
- 13.06
- 2.4
- 17.93
- 13.42
- Sunil Healthcare
- -
- 1.05
- 3.3
- 1.73
- Godavari Drugs
- 12.71
- 1.83
- 15.19
- 2.98
Vasundhara Rasayans Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 10-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results
- 07-Sept-24
- Final Dividend & A.G.M.
- 14-Aug-24
- Quarterly Results
- 28-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 01-Aug-23
- Qtrly Results, Final Dividend & A.G.M.
- 29-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 29-Aug-23
- 01-Aug-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 09-Sept-24
- -
- 23-Sept-24
- 2
- 01-Aug-23
- -
- 22-Aug-23
- 2
- 25-Aug-22
- -
- 22-Sept-22
- 1
- 30-Jun-21
- -
- 22-Sept-21
- 1.5
